Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Addison's disease secondary prevention

Introduction

Overview

Overview

Effective measures for the secondary prevention of Addison’s disease include wearing an identification bracelet stating the name of the disease to ensure proper emergency treatment during an adrenal crisis. Patients diagnosed with Addison’s disease and their family members should also be educated about risks of hormone replacement therapy and dose adjustments during periods of acute illnesses. Immediate medical attention must be given when severe infections, vomiting, or diarrhea occur.

Secondary Prevention

Secondary Prevention

Effective measures for the secondary prevention of Addison’s disease include:_NIDDK-1|[1][2]

  • Patients diagnosed with adrenal insufficiency must always carry identification card stating the name of the disease to ensure proper treatment in case of an emergency.
    • The card should alert emergency personnel about the need to inject 100 mg of cortisol in situations of emergency.
    • The card should also include the doctor’s name and telephone number and the name and telephone number of the nearest relative to be notified.
  • When traveling, a needle, syringe, and an injectable form of cortisol should be carried for emergencies.
  • Patients diagnosed with Addison’s disease should know how to increase medication during periods of stress or mild upper respiratory infections.
  • Immediate medical attention is needed when severe infections, vomiting, or diarrhea occur. These conditions can precipitate an Addisonian crisis.
  • Patients, diagnosed with Addison’s disease, who is vomiting may require injections of hydrocortisone.
References

References

  1. _NIDDK_1-0|↑ “Adrenal Insufficiency & Addison’s Disease | NIDDK”.
  2. ↑ Napier C, Pearce SH (2012). “Autoimmune Addison’s disease”. Presse Med. 41 (12 P 2): e626–35. doi:10.1016/j.lpm.2012.09.010. PMID 23177474.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]